Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | PLAU | P00749 | 2/20 | 0.33 |
| ▸ | PLG | P00747 | 1/20 | 0.33 |
| ▸ | PLAT | P00750 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25406694 | 0.77 | RECQL (0.37) | KDM4EMEN1USP2TP53HSP90AA1 | |
| SCHEMBL582930 | 0.74 | PLAU (0.56) | KDM4EMEN1HTTKMT2ASMN1; SMN2 | |
| SCHEMBL30497136 | 0.74 | PLAU (0.56) | KDM4EMEN1HTTKMT2ASMN1; SMN2 | |
| SCHEMBL6223301 | 0.73 | — | — | |
| SCHEMBL30470394 | 0.71 | PLAU (0.56) | KDM4EMEN1USP2TP53HSP90AA1 | |
| SCHEMBL582273 | 0.71 | PLAU (0.56) | KDM4EMEN1USP2TP53HSP90AA1 | |
| SCHEMBL29024926 | 0.71 | CTDSP1 (0.50) | KDM4EMEN1TP53HSP90AA1HTT | |
| SCHEMBL31536066 | 0.70 | KDM4E (0.35) | KDM4EMEN1USP2TP53HSP90AA1 | |
| SCHEMBL277425 | 0.69 | KDM4E (0.53) | KDM4EHTTMAPT | |
| SCHEMBL31388388 | 0.68 | PLAU (0.41) | KDM4EMEN1KMT2ASMN1; SMN2PLAU |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6977261-B2 | Azaisoquinoline derivatives as matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY LLC (US) | 2005-12-20 | — | — | US | disclosed |
| EP-1539709-A1 | AZAISOQUINOLINE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | Warner-Lambert Company LLC (US) | 2005-06-15 | — | — | EP | disclosed |
| US-20040038961-A1 | Azaisoquinoline derivatives as matrix metalloproteinase inhibitors | BUNKER AMY MAE (US) | 2004-02-26 | — | — | US | disclosed |
| WO-2004014866-A1 | AZAISOQUINOLINE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038961-A1 | Azaisoquinoline derivatives as matrix metalloproteinase inhibitors | MMP13, MMP9, MMP1 | KDM4E 462/4885MEN1 2472/4885USP2 3596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.